Page 3 - Timothys Ernst News Today

FORA Capital LLC raised its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) by 34.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,569 shares of the medical research company’s stock after buying an additional 400 shares during […]

Russell Investments Group Ltd. cut its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) by 11.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 60,365 shares of the medical research company’s stock after selling 7,564 shares during the period. Russell Investments Group […]

Toronto Dominion Bank increased its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) by 18.1% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 11,917 shares of the medical research company’s stock after purchasing an additional 1,830 shares during the period. […]

Metis Global Partners LLC lifted its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) by 33.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 664 shares of the medical research company’s stock after buying an additional 166 shares during the quarter. […]

Bio-Rad Laboratories (NYSE:BIO – Get Rating) issued its earnings results on Thursday. The medical research company reported $3.34 earnings per share for the quarter, topping the consensus estimate of $3.24 by $0.10, Briefing.com reports. Bio-Rad Laboratories had a positive return on equity of 4.19% and a negative net margin of 7.01%. The business had revenue […]

Bio-Rad Laboratories (NYSE:BIO – Get Rating) released its quarterly earnings results on Thursday. The medical research company reported $3.34 earnings per share for the quarter, topping the consensus estimate of $3.24 by $0.10, Briefing.com reports. The business had revenue of $676.80 million for the quarter, compared to analysts’ expectations of $689.28 million. Bio-Rad Laboratories had […]

Bio-Rad Laboratories (NYSE:BIO – Get Rating) announced its earnings results on Thursday. The medical research company reported $3.34 EPS for the quarter, topping analysts’ consensus estimates of $3.24 by $0.10, Briefing.com reports. Bio-Rad Laboratories had a positive return on equity of 4.59% and a negative net margin of 129.66%. The firm had revenue of $676.80 […]

Bio-Rad Laboratories (NYSE:BIO – Get Rating) announced its quarterly earnings results on Thursday. The medical research company reported $3.34 earnings per share for the quarter, beating the consensus estimate of $3.24 by $0.10, Briefing.com reports. The company had revenue of $676.80 million during the quarter, compared to analysts’ expectations of $689.28 million. Bio-Rad Laboratories had […]

Bio-Rad Laboratories (NYSE:BIO – Get Rating) will post its quarterly earnings results after the market closes on Thursday, May 4th. Analysts expect Bio-Rad Laboratories to post earnings of $3.24 per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link. Bio-Rad Laboratories (NYSE:BIO – Get […]

Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.